Tesetaxel for Previously Treated Patients With Bladder Cancer
The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a promising treatment option for some patients.

Tesetaxel is an orally administered taxane that is in development as treatment for subjects with advanced cancers. This study is being conducted to determine the efficacy and safety of tesetaxel administered to patients previously treated with chemotherapy for progressive metastatic transitional cell carcinoma of the urothelium.
Carcinoma, Transitional Cell
DRUG: Tesetaxel
Response rate (revised RECIST), Proportion of patients with a confirmed complete or partial response, 12 months from date of first dose of study medication for last patient enrolled
≥ 3-month response rate, Proportion of patients with a confirmed complete or partial response ≥ 3 months in duration, 12 months from date of first dose of study medication for last patient enrolled|Disease control rate, Proportion of patients with a confirmed complete or partial response of any duration or stable disease ≥ 3 months in duration, 12 months from date of first dose of study medication for last patient enrolled|Durable response rate, Proportion of subjects with a confirmed complete or partial response ≥ 6 months in duration, 12 months from date of first dose of study medication for last patient enrolled|Duration of response, Date when response criteria are first met to the date when progression is first documented, 12 months from date of first dose of study medication for last patient enrolled|Time to progression, Date of first dose of study medication to the date when progression is first documented, 12 months from date of first dose of study medication for last patient enrolled|Safety, Adverse events and clinical laboratory tests, Up to 30 days after the last dose of study medication for a specific patient
The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a promising treatment option for some patients.

Tesetaxel is an orally administered taxane that is in development as treatment for subjects with advanced cancers. This study is being conducted to determine the efficacy and safety of tesetaxel administered to patients previously treated with chemotherapy for progressive metastatic transitional cell carcinoma of the urothelium.